AU2012343536B2 - Immunogenic treatment of cancer - Google Patents

Immunogenic treatment of cancer Download PDF

Info

Publication number
AU2012343536B2
AU2012343536B2 AU2012343536A AU2012343536A AU2012343536B2 AU 2012343536 B2 AU2012343536 B2 AU 2012343536B2 AU 2012343536 A AU2012343536 A AU 2012343536A AU 2012343536 A AU2012343536 A AU 2012343536A AU 2012343536 B2 AU2012343536 B2 AU 2012343536B2
Authority
AU
Australia
Prior art keywords
cancer
tumour
immunomodulator
therapy
cell death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012343536A
Other languages
English (en)
Other versions
AU2012343536A1 (en
Inventor
Charles AKLE
John Grange
Satvinder MUDAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immodulon Therapeutics Ltd
Original Assignee
Immodulon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immodulon Therapeutics Ltd filed Critical Immodulon Therapeutics Ltd
Publication of AU2012343536A1 publication Critical patent/AU2012343536A1/en
Application granted granted Critical
Publication of AU2012343536B2 publication Critical patent/AU2012343536B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012343536A 2011-12-02 2012-12-03 Immunogenic treatment of cancer Active AU2012343536B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy
GB1120779.2 2011-12-02
PCT/GB2012/052992 WO2013079980A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer

Publications (2)

Publication Number Publication Date
AU2012343536A1 AU2012343536A1 (en) 2014-06-05
AU2012343536B2 true AU2012343536B2 (en) 2017-08-24

Family

ID=45509083

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012343536A Active AU2012343536B2 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer

Country Status (15)

Country Link
US (4) US20140356397A1 (https=)
EP (1) EP2785361B1 (https=)
JP (1) JP6085611B2 (https=)
KR (1) KR20140097419A (https=)
CN (1) CN104023733A (https=)
AU (1) AU2012343536B2 (https=)
BR (1) BR112014012880A2 (https=)
CA (1) CA2857429A1 (https=)
GB (1) GB201120779D0 (https=)
IL (1) IL232890A0 (https=)
IN (1) IN2014MN00955A (https=)
MX (1) MX2014006511A (https=)
RU (1) RU2014121335A (https=)
SG (1) SG11201402396XA (https=)
WO (1) WO2013079980A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
WO2015038832A1 (en) 2013-09-11 2015-03-19 The Board Of Trustees Of The Leland Stanford Junior University Arrays of accelerating structures and rapid imaging for facilitating rapid radiation therapies
JP6723153B2 (ja) 2013-12-05 2020-07-15 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー 生体内の望ましくない軟部組織を切除するシステム
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
KR102128856B1 (ko) * 2015-01-30 2020-07-02 알에프이엠비 홀딩스, 엘엘씨 고주파 전기적 막 파괴를 이용하여 생명체의 바람직하지 않은 연조직을 절제하는 시스템
KR20180015269A (ko) * 2015-06-24 2018-02-12 이모듈런 테라퓨틱스 리미티드 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포
RU2596505C1 (ru) * 2015-07-02 2016-09-10 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ лечения онкологических больных цитотоксическими лимфоцитами
US10478194B2 (en) * 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
EP3402517B1 (en) 2016-01-15 2025-08-20 RFEMB Holdings, LLC Immunologic treatment of cancer by using a tumor ablation technic together with a combination of a ctla-4 inhibitor, a pd-1 inhibitor and gm-csf
RU2018136347A (ru) * 2016-04-14 2020-05-14 Фелдрайх Каро Руиз Аб Аппарат для радиационной терапии, включающий модуль ионизации и источник ультрафиолетового света
JP2020512151A (ja) 2017-03-28 2020-04-23 エンブレーション リミテッドＥｍｂｌａｔｉｏｎ Ｌｉｍｉｔｅｄ 狭窄の処置
EP3654976A1 (en) 2017-07-21 2020-05-27 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы
EA202191556A1 (ru) 2018-12-03 2021-10-14 Фьюжн Фармасьютикалз Инк. Комбинированная терапия радиоиммуноконъюгатами и ингибиторами контрольных точек
US20220098578A1 (en) * 2019-01-31 2022-03-31 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
EP4082577A4 (en) * 2019-12-27 2024-01-03 Zeria Pharmaceutical Co., Ltd. CANCER TREATMENT METHOD AND DRUG
EP4376945A1 (en) * 2021-07-27 2024-06-05 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
CA2095855C (en) * 1990-11-08 2003-04-29 Graham A.W. Rook Mycobacterium as adjuvant for antigens
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
AU4281200A (en) 1999-04-23 2000-11-10 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
AU2002353366A1 (en) * 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
EP1575500A4 (en) 2002-07-12 2007-01-03 Univ Johns Hopkins MESOTHELIN VACCINE AND MODEL SYSTEMS
CA2626547A1 (en) 2005-10-21 2007-05-03 Medical College Of Georgia Research Institute, Inc. The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) 2005-12-21 2006-02-01 Bioeos Ltd Method
US8557257B2 (en) * 2006-03-24 2013-10-15 Oncovac Inc. Mycobacterial immunotherapy for cancer treatment
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2012122471A2 (en) * 2011-03-09 2012-09-13 The Johns Hopkins University Compounds and methods of use in ablative radiotherapy
PL2172211T3 (pl) * 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
US8617520B2 (en) 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
KR20220062143A (ko) 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
KR20180015269A (ko) 2015-06-24 2018-02-12 이모듈런 테라퓨틱스 리미티드 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포
CA3104218A1 (en) 2018-06-25 2020-01-02 Immodulon Therapeutics Limited Cancer therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HROUDA et al. "Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer", BJU International, 2000, Vol. 86, Pages 742-748. *
O’BRIEN et al., British Journal of Cancer, 2000, Vol. 83, No. 7, Pages 853–857. *
STEBBING et al. "An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma", Annals of Oncology, 2012, Vol. 23, Pages 1314–1319. *
SUR PRABIR KUMAR ET AL., JOURNAL OF THE INDIAN MEDICAL ASSOCIATION, INDIAN MEDICAL ASSOCIATION, CALCUTTA, IN, (20030101), vol. 101, no. 2, ISSN 0019-5847, page 118,120. *
Yuk et al. "Bacillus Calmette-Guerin cell wall cytoskeleton enhances colon cancer radiosensitivity through autophagy", Autophagy, 2010, Vol. 6, No. 1, Pages 46-60. *

Also Published As

Publication number Publication date
GB201120779D0 (en) 2012-01-11
JP6085611B2 (ja) 2017-02-22
JP2014533743A (ja) 2014-12-15
US20200338181A1 (en) 2020-10-29
RU2014121335A (ru) 2016-01-27
US11554166B2 (en) 2023-01-17
MX2014006511A (es) 2014-12-05
CA2857429A1 (en) 2013-06-06
US20140356397A1 (en) 2014-12-04
BR112014012880A2 (pt) 2017-06-13
IL232890A0 (en) 2014-07-31
CN104023733A (zh) 2014-09-03
SG11201402396XA (en) 2014-10-30
NZ624994A (en) 2016-10-28
US20230149525A1 (en) 2023-05-18
WO2013079980A1 (en) 2013-06-06
AU2012343536A1 (en) 2014-06-05
EP2785361A1 (en) 2014-10-08
US20190224294A1 (en) 2019-07-25
IN2014MN00955A (https=) 2015-04-24
US11318193B2 (en) 2022-05-03
KR20140097419A (ko) 2014-08-06
EP2785361B1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
US20230149525A1 (en) Immunogenic treatment of cancer
Breton et al. Microsecond and nanosecond electric pulses in cancer treatments
JP2025185047A (ja) がんの免疫学的処置
US9526911B1 (en) Immune mediated cancer cell destruction, systems and methods
Impellizeri et al. Electroporation in veterinary oncology
CN102740874A (zh) 肿瘤液化的方法和组合物
CN103800896A (zh) 一种自体肿瘤疫苗的制备方法及其应用
Rampersaud et al. Hyperthermia as a treatment for bladder cancer
Tranberg Local destruction of tumors and systemic immune effects
Alshaibi et al. Modulated electrohyperthermia: A new hope for cancer patients
Yan et al. Endoscopic Ultrasound‐Guided Intratumoural Therapy for Pancreatic Cancer
Yang et al. Status and Prospects of Glioblastoma Multiforme Treatments
Guo et al. Role of endoscopic ultrasound in treatment of pancreatic cancer
NZ624994B2 (en) Immunogenic treatment of cancer
Zhang et al. Inhibitory and immunological effects induced by the combination of photodynamic therapy and dendritic cells on mouse transplanted hepatoma
Stam et al. From local to systemic treatment: leveraging antitumor immunity following irreversible electroporation
RU2530523C2 (ru) Способ противоопухолевой иммунотерапии
Li et al. Laser immunotherapy: Concept, possible mechanism, clinical applications, and recent experimental results
US20210154296A1 (en) Vaccine or immunotherapeutic agent composition containing photothermally treated cell lysates as active ingredients
CN104083205A (zh) 一种肿瘤治疗系统和方法
李晓松 et al. Laser immunotherapy: Novel modality to treat cancer through specific antitumor immune response
Sugihara et al. Metronomic Photodynamic Therapy With Immune Checkpoint Inhibitors Does Not Affect Nontarget Lesions
Testoni et al. Present and Future of Local Therapies for Unresectable Pancreatic Cancer
Nuccitelli Nanosecond Pulsed Field Ablation in Oncology. Medical Research Archives,[online] 13 (8)
Keisari et al. In situ ablation of solid tumors by electric forces and its effect on the tumor microenvironment and anti-tumor immunity

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)